|
1.
|
|
10 p, 396.0 KB |
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events : The ODYSSEY OUTCOMES Trial
/
Szarek, Michael (State University of New York) ;
White, Harvey D. (University of Auckland and Green Lane Cardiovascular Services Auckland City Hospital) ;
Schwartz, Gregory G. (Division of Cardiology. University of Colorado School of Medicine) ;
Alings, Marco (Amphia Ziekenhuis Molengracht) ;
Bhatt, Deepak L (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Chiang, Chern-En (Taipei Veterans General Hospital and National Yang-Ming University) ;
Diaz, Rafael (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Goodman, Shaun G. (University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, R.A. (Stanford University) ;
Jukema, J.Wouter (Leiden University Medical Center) ;
Kimura, Takeshi (Kyoto University Graduate School of Medicine) ;
Kiss, Robert Gabor (Magyar Honvédség Egészségügyi Központ) ;
Lecorps, Guillaume (Sanofi) ;
Mahaffey, Kenneth W. (Stanford University) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals Inc.) ;
Roe, Matthew T. (Duke University Medical Center) ;
Tricoci, Pierluigi (Duke University Medical Center) ;
Xavier, Denis (St. John's Medical College and Research Institute) ;
Zeiher, Andreas Michael (Goethe University) ;
Steg, Ph Gabriel (Royal Brompton Hospital (Londres)) ;
Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge) ;
Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. [...]
2019 -  10.1016/j.jacc.2018.10.039
Journal of the American College of Cardiology, Vol. 73 Núm. 4 (may 2019) , p. 387-396
|
|
|
2.
|
|
10 p, 324.1 KB |
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial
/
Jukema, J.Wouter (Leiden University Medical Center) ;
Szarek, Michael (State University of New York) ;
Zijlstra, Laurien E. (Leiden University Medical Center) ;
de Silva, H.Asita (University of Kelaniya) ;
Bhatt, Deepak L (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Diaz, Rafael (Cardiovascular Institute of Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Goodman, Shaun G. (St. Michael's Hospital. University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Stanford University) ;
Karpov, Yuri (Russian Cardiological Scientific-Productive Complex) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals. Inc.) ;
Prieto, Juan C. (University of Chile Clinical Hospital) ;
Roe, Matthew T. (Duke University School of Medicine) ;
White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ;
Zeiher, Andreas Michael (Goethe University) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Steg, P.Gabriel (Royal Brompton Hospital (Londres)) ;
Cequier, Ángel (Hospital Universitari de Bellvitge) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Mata Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. [...]
2019 - 10.1016/j.jacc.2019.03.013
Journal of the American College of Cardiology, Vol. 74 Núm. 9 (march 2019) , p. 1167-1176
|
|
|
3.
|
|
17 p, 3.0 MB |
Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration
/
Mendieta, G. (Clinic Hospital) ;
Ben-Aicha Gonzalez, Soumaya (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Gutiérrez, M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Casaní, Laura (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Aržanauskaitė, M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Carreras, F. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Sabate, M. (Clinic Hospital) ;
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau) ;
Vilahur, Gemma (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Beyond lipid-lowering, statins exert cardioprotective effects. High-dose statin treatment seems to reduce cardiovascular complications in high-risk patients. The ideal timing and administration regime remain unknown. [...]
2020 - 10.1016/j.jacc.2020.01.042
Journal of the American College of Cardiology, Vol. 75 Núm. 12 (31 2020) , p. 1386-1402
|
|
|
4.
|
|
12 p, 648.4 KB |
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
/
Bittner, Vera A. (University of Alabama at Birmingham) ;
Szarek, Michael (State University of New York) ;
Aylward, Philip (South Australian Health and Medical Research Institute) ;
Bhatt, Deepak L. (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ;
Díaz, Rafaël J. (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Fras, Zlatko (Univerza V Ljubljani) ;
Goodman, Shaun G. (University of Toronto) ;
Halvorsen, Sigrun (University of Oslo) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Stanford University) ;
Jukema, J. Wouter (Leiden University Medical Center) ;
Loizeau, Virginie (Sanofi) ;
Moriarty, Patrick Maurice (University of Kansas Medical Center) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals Inc.) ;
Roe, Matthew T. (Duke University School of Medicine) ;
Sinnaeve, Peter (University of Leuven) ;
Tsimikas, Sotirios (University of California San Diego) ;
Vogel, Robert A. (University of Colorado School of Medicine) ;
White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ;
Zahger, Doron (Soroka University Medical Center) ;
Zeiher, Andreas Michael (Goethe University) ;
Steg, Philippe Gabriel (Royal Brompton Hospital (Londres)) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Cequier, Ángel (Hospital Universitari de Bellvitge) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). [...]
2020 - 10.1016/j.jacc.2019.10.057
Journal of the American College of Cardiology, Vol. 75 Núm. 2 (21 2020) , p. 133-144
|
|
|
5.
|
|
33 p, 1.7 MB |
Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials
/
Ibanez, Borja (Hospital Universitario Fundación Jiménez Díaz) ;
Aletras, Anthony H. (Skåne University Hospital (Suècia)) ;
Arai, Andrew E. (National Heart, Lung, and Blood Institute (Bethesda, Estats Units d'Amèrica)) ;
Arheden, Hakan (Skåne University Hospital (Suècia)) ;
Bax, Jeroen (Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Leiden, the Netherlands) ;
Berry, Colin (University of Glasgow. Glasgow Cardiovascular Research Centre) ;
Bucciarelli-Ducci, Chiara (University of Bristol. Bristol Heart Institute) ;
Croisille, Pierre (University Lyon, UJM-Saint-Etienne, INSA, CNRS UMR 5520, INSERM U1206, CREATIS, F-42023, Saint-Etienne, France) ;
Dall'Armellina, Erica (Leeds Institute of Cardiovascular and Metabolic Medicine, Department of Biomedical Imaging Sciences, University of Leeds, Leeds, United Kingdom) ;
Dharmakumar, Rohan (Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, and Division of Cardiology, Department of Medicine, University of California, Los Angeles, California) ;
Eitel, Ingo (University Heart Center Lübeck, Medical Clinic II (Cardiology/ Angiology/Intensive Care Medicine) and German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany) ;
Fernández-Jiménez, Rodrigo (Cardiology Department, Icahn School of Medicine at Mount Sinai, New York, New York) ;
Friedrich, Matthias G. (Department of Medicine, Heidelberg University, Heidelberg, Germany) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hausenloy, Derek J. (Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico) ;
Kim, Raymond J. (Duke Cardiovascular Magnetic Resonance Center, Division of Cardiology, and Department of Radiology, Duke University Medical Center, Durham, North Carolina) ;
Kozerke, Sebastian (Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland) ;
Kramer, Christopher M. (Departments of Medicine and Radiology, University of Virginia Health System, Charlottesville, Virginia) ;
Salerno, Michael (Departments of Medicine and Radiology, University of Virginia Health System, Charlottesville, Virginia; and) ;
Sánchez-González, Javier (Philips Healthcare, Madrid, Spain) ;
Sanz, Javier (Cardiology Department, Icahn School of Medicine at Mount Sinai, New York, New York) ;
Fuster, Valentín (Cardiology Department, Icahn School of Medicine at Mount Sinai, New York, New York) ;
Universitat Autònoma de Barcelona
After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). [...]
2019 - 10.1016/j.jacc.2019.05.024
Journal of the American College of Cardiology, Vol. 74 (july 2019) , p. 238-256
|
|
|
6.
|
|
10 p, 559.2 KB |
Genetic etiology for alcohol-induced cardiac toxicity
/
Ware, James S. (Imperial College London. National Heart and Lung Institute) ;
Amor-Salamanca, Almudena (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Tayal, Upasana (Imperial College London. National Heart and Lung Institute) ;
Govind, Risha (Imperial College London. National Heart and Lung Institute) ;
Serrano, Isabel (Hospital Universitari Joan XXIII de Tarragona) ;
Salazar-Mendiguchía, Joel (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
García-Pinilla, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Pascual-Figal, Domingo A. (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Núñez, Julio (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ;
Guzzo-Merello, Gonzalo (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
González-Vioque, Emiliano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Bardají, Alfredo (Hospital Universitari Joan XXIII de Tarragona) ;
Manito, Nicolas (Hospital Universitari de Bellvitge) ;
López-Garrido, Miguel A. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Padron-Barthe, Laura (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Edwards, Elizabeth (Imperial College London. National Heart and Lung Institute) ;
Whiffin, Nicola (Imperial College London. National Heart and Lung Institute) ;
Walsh, Roddy (Imperial College London. National Heart and Lung Institute) ;
Buchan, Rachel J. (Imperial College London. National Heart and Lung Institute) ;
Midwinter, William (Imperial College London. National Heart and Lung Institute) ;
Wilk, Alicja (Imperial College London. National Heart and Lung Institute) ;
Prasad, Sanjay (Imperial College London. National Heart and Lung Institute) ;
Pantazis, Antonis (Royal Brompton and Harefield. Cardiovascular Research Centre) ;
Baski, John (Royal Brompton and Harefield. Cardiovascular Research Centre) ;
O'Regan, Declan P. (Imperial College London. MRC London Institute of Medical Sciences) ;
Alonso-Pulpón, Luis (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Cook, Stuart A. (Imperial College London. National Heart and Lung Institute) ;
Lara-Pezzi, Enrique (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ;
Barton, Paul J. (Imperial College London. National Heart and Lung Institute) ;
García-Pavía, Pablo (Universidad Francisco de Vitoria)
Alcoholic cardiomyopathy (ACM) is defined by a dilated and impaired left ventricle due to chronic excess alcohol consumption. It is largely unknown which factors determine cardiac toxicity on exposure to alcohol. [...]
2018 - 10.1016/j.jacc.2018.03.462
Journal of the American College of Cardiology, Vol. 71, issue 20 (May 2018) , p. 2293-2302
|
|
visitante ::
identificación
